Clinical Trial Goal
To find out if the combination of ibrutinib, obinutuzumab and venetoclax is safe and works well to treat follicular lymphoma that has not yet been treated
You may be able to join this trial if you:
- Are 18 years old or older
- Have follicular lymphoma that has not yet been treated
- Do not have lymphoma in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Ibrutinib is a small molecule inhibitor that blocks BTK in certain cells.
Obinutuzumab is a monoclonal antibody that targets CD20 on certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last a month. In each cycle, you'll get:
Obinutuzumab is a monoclonal antibody that targets CD20 on certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last a month. In each cycle, you'll get:
- Ibrutinib – Given as a pill that you take by mouth each day
- Obinutuzumab – Given as intravenous (IV) infusions 0, 1 or 3 days of each cycle
- Venetoclax – Given as a pill that you take by mouth each day
You may continue treatment for up to 2 years. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 4 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this combination to treat follicular lymphoma is new and unproven.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this combination to treat follicular lymphoma is new and unproven.
Locations
University of California, Los AngelesNOT_YET_RECRUITING
Los Angeles, California
Shenetra Walker, 310-582-4067, SKWalker@mednet.UCLA.edu
University of California Davis Comprehensive Cancer CenterRECRUITING
Sacramento, California
Selina Laqui, 916-734-0565, sblaqui@ucdavis.edu
University of California, San DiegoRECRUITING
San Diego, California
Benjamin Heyman, MD, 8582463038, BHeyman@health.ucsd.edu
University of California, San Francisco (UCSF) FresnoRECRUITING
Fresno, California
Lizbeth Gasga, 559-387-1827, lizbeth.gasgasanchez@ucsf.edu
Sponsors
collaborator: National Cancer Institute (NCI), collaborator: Pharmacyclics LLC., collaborator: Genentech, Inc., lead: Joseph Tuscano
